Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
PIXIUM VISION | Corporate | TP EUR3.4 vs EUR5.3 Combination with Second Sight, a smart way to raise funds -> Pixium Vision to become a holding -> A combination to finance Prima system development -> Target Price decreased to EUR3.4 due to lower peak sales
PIXIUM VISION - CORPORATE | EUR5,3 vs EUR5,5 1H 19 : Structuring the development and regulatory strategy New CEO brings deep expertise New strategy triggers delay but increases likelihood of success Building a strong US network Adjusting our fair value to reflect delayed time to market
PIXIUM VISION - CORPORATE | EUR5,5 Sustained 12 months results for PRIMA Successfully building on positive 6 months results Efficacy continues to exceed expectations Clear cut safety confirms risk-benefit US development should not be overlooked
PIXIUM VISION - CORPORATE | EUR5,5(+235%) Expected impairment of IRIS. 2018YE cash position of EUR15.6m Strong non-R&D costs management Expected impairment of IRIS following the successes of PRIMA EUR15.6m cash position offers visibility on 2019 activities Reiterate FV or EUR5.5/share
PIXIUM VISION - CORPORATE | EUR5.5 vs. 4,1(+216%) Starting 2019 by clearing a significant milestone Positive interim results for PRIMA at 6 months Supportive for the initiation of a pivotal CE mark trial Blockbuster profile confirmed and FV up to EUR5.5/share
PIXIUM VISION | Love is No Longer Blind | Corporate, FV EUR4.1 initiation of coverage Pixium Vision is a French medtech company positioned in the growing retinal implants market. The group is now fully focused on PRIMA, its most advanced proprietary platform which has the potential to partially restore central vision loss in patients suffering from advanced dry-AMD, a high unmet need with >2m patients suffering from the disease in Europe and the US. The de-risked 6 months interim results from th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.